| 笔克远东(00752) | 2.900 | 2.960 | 1.37% | | --- | --- | --- | --- | | 东吴水泥(00695) | 9.580 | 9.990 | 1.32% | | 天虹国际集团(02678) | 5.720 | 5.720 | 1.24% | | 渣打集团(02888) | 204.200 | 204.400 | 1.19% | | 明梁控股(08152) | 0.088 | 0.088 | 1.15% | | 电能实业(00006) | 61.750 | 62.100 | 1.14% | | 太古股份公司Ａ(00019) | 77.550 | 77.600 | 1.11% | | 湾区发展(00737) | 1.900 | 1.920 | 1.05% | | 春城热力(01853) | 2.000 | 2.000 | 1.01% | | 硬蛋创新(00400) | 4.050 | 4.100 | 0.99% | | 健康１６０(02656) | 87.050 | 88.400 | 0.91% | | Ａ南方人民币(03122) | 189.800 | 18 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康160国际有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02656 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50, ...

Core Insights - The global tech giants are intensifying their efforts in the AI healthcare sector, with Chinese companies adopting pragmatic approaches that are becoming essential [1] - The AI healthcare market in China is experiencing rapid growth, driven by an aging population and a structural imbalance in quality medical resources [7] Group 1: Major Players and Their Strategies - OpenAI's ChatGPT Health focuses on consumer engagement, allowing users to upload medical records for personalized health advice, processing over 230 million health interactions weekly [2] - Google has launched the MedGemma 1.5 model, which operates offline and supports 3D scanning and medical text analysis, with a speech-to-text error rate of only 5.2% [2] - Anthropic targets the enterprise market with Claude for Healthcare, emphasizing privacy and compliance, and has partnered with institutions like Boston Children's Hospital [2] Group 2: Chinese Companies' Developments - Health 160 has connected over 44,800 healthcare institutions and developed an AI health management system that covers the entire patient journey, achieving a content click-through rate increase of 90% [3][4] - JD Health aims to evolve AI from a tool to a core engine for personalized health management, launching the "Zhi Yi" AI for evidence-based medicine [5][6] - JD Health's AI initiatives include a comprehensive health service matrix and specialized systems for cancer treatment, showcasing the potential of AI in personalized medicine [6] Group 3: Market Trends and Challenges - The AI medical device market in China is projected to grow from 292 million yuan in 2020 to 24.2 billion yuan by 2025, highlighting the sector's rapid expansion [7] - The competitive focus in AI healthcare is shifting from utility to stable, compliant, and sustainable implementation, with ecological layouts being crucial for achieving these goals [7] - Challenges include data privacy, ethical standards, and the need for improved data quality and interoperability among healthcare systems [8] Group 4: Future Directions - The future of AI healthcare in China will see a complementary relationship between major players' comprehensive strategies and targeted niche developments [9] - As technology matures, AI models are expected to further empower the healthcare industry, shifting the focus from treatment to proactive health management [9]

Core Viewpoint - As of January 15, a total of 105 stocks reached their 52-week highs, with notable performers including 德莱建业 (01546), 东曜药业－Ｂ (01875), and 大森控股 (01580) achieving high rates of 78.00%, 51.36%, and 37.61% respectively [1]. Summary by Category 52-Week Highs - 德莱建业 (01546) closed at 0.355, with a peak of 0.445, marking a high rate of 78.00% [1]. - 东曜药业－Ｂ (01875) closed at 4.190, reaching a high of 4.450, with a high rate of 51.36% [1]. - 大森控股 (01580) closed at 0.275, with a peak of 0.300, achieving a high rate of 37.61% [1]. - 顺兴集团控股 (01637) and 怡园酒业 (08146) also showed significant increases, with high rates of 36.36% and 24.74% respectively [1]. Additional Notable Stocks - JBB BUILDERS (01903) reached a high rate of 24.12% with a closing price of 2.830 [1]. - 天臣控股 (01201) and 江苏创新 (02116) had high rates of 15.38% and 15.00% respectively [1]. - 万国黄金集团 (03939) and 竣球控股 (01481) also performed well, with high rates of 12.95% and 12.44% respectively [1]. 52-Week Lows - The report also noted stocks reaching 52-week lows, with 天彩控股 (03882) showing a low rate of -14.42% [3]. - 中国智慧能源 (01004) and 基石控股 (01592) followed with low rates of -13.64% and -12.86% respectively [3]. - 弘毅文化集团－旧 (02990) and 中原建业 (09982) also reported significant declines of -9.09% and -6.06% respectively [3].

Summary of Key Points Core Viewpoint - As of January 9, a total of 73 stocks reached their 52-week highs, with notable performances from Lingxiong Technology (02436), Delai Construction (01546), and Zhipu (02513) showing significant growth rates of 104.99%, 38.89%, and 22.22% respectively [1]. 52-Week Highs - Lingxiong Technology (02436) closed at 11.760, with a peak price of 15.600, achieving a high rate of 104.99% [1]. - Delai Construction (01546) closed at 0.161, reaching a maximum of 0.250, with a high rate of 38.89% [1]. - Zhipu (02513) had a closing price of 158.600 and a peak of 165.000, resulting in a high rate of 22.22% [1]. - Other notable stocks include Asia Pacific Satellite (01045) with a high rate of 20.64% and Rongda Technology (09881) at 12.87% [1]. 52-Week Lows - The stocks reaching their 52-week lows include Lishi International (00842) with a closing price of 0.850, marking a decline of 39.29% [2]. - Bokan Vision Cloud - B (02592) closed at 2.930, with a decrease of 16.90% [2]. - Lingzai Technology Finance (00093) reached a low of 0.485, reflecting a drop of 14.77% [2].

2025年12月下旬，开盘证券等机构发布针对健康160（02656.HK）的评级报告，最高目标价达到95.51港 元，引发市场广泛关注。 作为国内领先的数字医疗健康综合服务平台，健康160凭借超过18年的行业深耕，在平台挂号量、合作 医疗机构及医护人员数量等核心资源指标上均位列行业第一。券商研究所的乐观预期正是源于健康160 展现出的明确业绩拐点信号：营收重回增长轨道，经调整净亏损大幅收窄，盈利在望。 健康160的业务构成呈现出鲜明的"医药产品经销与数字健康服务双轮驱动"特征。医药健康用品销售业 务贡献了公司收入的主要部分，但毛利率较低；而数字医疗健康解决方案虽然收入占比约30%，但毛利 率超过70%，成为公司盈利改善的关键动力。截至2025年3月31日，健康160的平台已连接超过4.46万家 医疗健康机构，其中包括超过1.44万家医院（含3430家三级医院）及超过3.02万家基层医疗卫生机构。 平台与超过90万名医护人员建立合作关系，注册个人用户达到5690万名。这些资源构成了健康160的核 心竞争壁垒。 行业风口：数字医疗赛道迎来黄金发展期 中国医疗健康行业正经历深刻变革。根据行业数据，数字医疗健康综合服 ...

Core Viewpoint - Health 160 is positioned as a leading digital healthcare service platform in China, showing clear signs of a performance turnaround with revenue growth and significantly reduced net losses, indicating a path to profitability [1][2]. Group 1: Financial Performance and Projections - Health 160's revenue is projected to grow from 6.58 billion to 11.49 billion CNY from 2025 to 2027, with growth rates of 6.00%, 21.80%, and 44.12% respectively [2]. - The company is expected to achieve net profits of -0.39 billion, 0.64 billion, and 2.58 billion CNY for the years 2025, 2026, and 2027, respectively, with a forecasted turnaround to profitability in 2026 [2]. Group 2: Business Model and Competitive Advantage - Health 160 operates on a dual-driven model of pharmaceutical distribution and digital health services, with the latter contributing higher profit margins (over 70%) despite a lower revenue share (approximately 30%) [4]. - The platform connects over 44,600 healthcare institutions, including more than 14,400 hospitals, and has established partnerships with over 900,000 healthcare professionals, creating a strong competitive barrier [4]. Group 3: Industry Trends and Growth Potential - The digital healthcare sector in China is experiencing rapid growth, with the market size expected to increase from 548 billion to 2,203 billion CNY, reflecting a compound annual growth rate (CAGR) of 32.1% [5]. - By 2030, the digital health service market is projected to reach 7,401 billion CNY, indicating significant growth potential for leading companies like Health 160 [5]. Group 4: Investment Value and Strategic Outlook - Health 160's investment value is driven by its unique resource and user base advantages, creating a strong network effect that is difficult to replicate [6]. - The company is expected to achieve full profitability by 2026, supported by the growth of high-margin AI medical and digital services [6]. - Future strategic initiatives may include expanding healthcare resource coverage, enhancing research capabilities, and exploring value-added services like commercial health insurance [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康160国际有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02656 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | ...

Core Viewpoint - Health 160 (02656.HK) announced the resignation of Zou Jun as an independent non-executive director and chairman of the audit committee, as well as member of the remuneration committee and nomination committee, effective December 12, 2025 [1] Group 1 - Zou Jun has resigned due to personal matters [1] - Wang Huan has been appointed as an independent non-executive director and chairman of the audit committee, as well as member of the remuneration committee and nomination committee, effective December 12, 2025 [1]

Group 1 - The company announced that Mr. Zou Jun has resigned from his position as an independent non-executive director and chairman of the audit committee, as well as member of the remuneration committee and nomination committee, effective from December 12, 2025 [1] - Mr. Wang Huan has been appointed as an independent non-executive director, chairman of the audit committee, and member of the remuneration committee and nomination committee, effective from December 12, 2025 [1]